Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of hepcidin kinetics after IL-6 receptor blockade in rheumatoid arthritis
NL-OMON33066Active, not recruiting
- Sponsor
- HagaZiekenhuis
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA) and anemia of inflammation (AI), sponsored by HagaZiekenhuis. Primary endpoint: Hepcidin levels at 24 hours. Started Apr 2010; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)anemia of inflammation (AI)
Beyond the preview
Go deeper on NL-OMON33066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33066.